Drug intelligence / Profile preview

caffeine + propranolol

Development stage
Unknown
Lead developer
Stanford University
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

Caffeine + propranolol is a combination of two active pharmaceutical ingredients, caffeine and propranolol. Caffeine is a central nervous system stimulant of the methylxanthine class, commonly used to promote wakefulness and as an adjuvant in pain relief medications. Propranolol is a non-selective beta-adrenergic receptor antagonist (beta blocker) used primarily for the treatment of hypertension, angina pectoris, arrhythmias, migraine prophylaxis, essential tremor, and anxiety. The combination does not have a widely recognized or marketed fixed-dose formulation but may be co-administered in clinical practice for specific indications such as migraine management or to counteract certain side effects (e.g., performance anxiety with fatigue). Caffeine acts by antagonizing adenosine receptors leading to increased alertness and mild vasoconstriction; propranolol blocks beta-1 and beta-2 adrenergic receptors resulting in decreased heart rate, contractility, blood pressure reduction, and inhibition of sympathetic nervous system activity[3][4][7][8]. There are no major direct pharmacological interactions between these two drugs; however, caffeine can reduce the antihypertensive effect of propranolol due to its pressor action[2][9].

02

Targets

ADRB1 (β1)ADORA2A (Adenosine A₂A Receptor)ADORA1 (Adenosine receptor A1 subtype)ADORA3 (Adenosine A3 receptor)ADRB2 (β2)ADORA2B (Adenosine A2B receptor)ADRB3 (β3)

Beyond the preview

Go deeper on caffeine + propranolol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on caffeine + propranolol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call